Notch3 drives development and progression of cholangiocarcinoma

Authors:

Abstract
Significance: Clinical outcomes in cholangiocarcinoma (CC) are poor; few patients are candidates for curative resection, and palliative chemotherapy produces only modest effects on survival. With an increasing incidence, new targets are urgently needed. Notch has been identified as having potential to induce CC when transgenically overexpressed, and this study aimed to characterize how endogenous Notch might drive tumorigenesis. We identify the atypical receptor Notch3 as differentially overactivated in CCs in humans, rats, and mice, with genetic deletion significantly reducing CC growth. Notch3 sustains tumor cell survival through PI3k/Akt activation via a noncanonical mechanism independent of Recombinant Signal Binding Protein for Immunoglobulin Kappa J Region (RBPJ), presenting an opportunity to target the pathway without disrupting classical Notch and bypassing toxicities associated with γ-secretase inhibitors.
Funding Information
  • Wellcome Trust (R52006)
  • European Research Council (ERC StG 311301)
  • Cancer Research UK (A12481 and A17196)
  • Cancer Research UK (A11650)
  • Cancer Research UK (R42296)

This publication has 27 references indexed in Scilit: